Kornimate/medical-research-clean huggingface dataset:
usability of the adapted rower for people with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the goal of this clinical trial is to examine usability of a locally built adaptive rower for people with spinal cord injury using an established and tested design. the main questions it aims to answer are: 1. what exercise intensity of activity do users achieve on the rower for steady state and interval rowing plans? 2. what assistance is required for setup and usage of the adaptive rower? 3. what do users think about the ease of use and what is their satisfaction with the adaptive rower? participants will complete a one-time exercise session with two adaptive rower bouts (10-15 minutes each) with a rest period in between.

a single group rolling prospective cohort study with a target of 15 participants will evaluate the initial design prototype using the an existing adaptive rower design. participants will have one visit to the university of south carolina rehabilitation lab. participants will receive an orientation to the rowing machine and available handle, grip and trunk support options. training will be provided in proper rowing technique and use of the rate of perceived exertion scale. participants will be fitted with a heart rate monitoring device and resting heart rate established. participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity. participants heart rate will be monitored and recorded throughout the testing period, with rate of perceived exertion at start, midpoint and end of steady state period, and at start, at each interval, and at end in interval period.

Eligibility criteria:
inclusion criteria: * use a wheelchair for mobility, * can perform the rowing motion with their arms * have enough grip strength to maintain grip on the rower handle with or without grip assist straps * are cleared to exercise through the electronic physical readiness questionnaire or physician release exclusion criteria: * current self-reported pressure wounds * pain with rowing motion.
mk0991 versus amphotericin b for empirical therapy in febrile, neutropenic pediatric patients (0991-044)

Conditions: Neutropenia; Fever

Summary: this study is a double-blind, randomized study of mk0991 versus liposomal amphotericin b in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (anc) below 500/microliter and who have fever despite broad antibiotic coverage. such patients would be candidates for empirical therapy with an intravenous anti-fungal agent.


Eligibility criteria:
inclusion criteria: * patients who are 2 through 17 years of age * absolute neutrophil count (anc) is below 500/microliter * have persistent fever (at least 4 days) despite antibiotic therapy
phi pilot study pafolacianine inject for intraoperative imaging on outcomes of gi cancer peritoneal carcinomatosis

Conditions: Gastrointestinal Cancer; Peritoneal Carcinomatosis

Summary: this is a pilot, single-arm, open label study to evaluate the ability of cytalux™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.


Eligibility criteria:
inclusion criteria: * adult patients 18 years of age and older * have a primary diagnosis of primary gastrointestinal cancer (of adenocarcinoma), planned for cytoreductive surgery * female patients must have a negative serum pregnancy test at screening, followed by a negative urine pregnancy test on the day of scheduled study drug infusion, or day of surgery * female patients of childbearing potential, or less than two (2) years postmenopausal, agree to use an acceptable form of contraception from time of signing informed consent until 30 days after study completion * ability to understand the requirements of the study, provide written informed consent for participation in the study and authorization of use and disclosure of protected health information, and agree to abide by study restrictions exclusion criteria: * previous exposure to cytalux™ (pafolacianine) * patients with known gastrointestinal cancer with carcinomatosis determined pre-operatively to be inoperable * any medical condition that in the opinion of the investigators could potential jeopardize the safety of the patient * history of anaphylactic reaction * history of allergy to any components of cytalux™ (pafolacianine), including folic acid * pregnancy, or positive pregnancy test * clinically significant abnormalities on ecg * impaired renal function defined as egfr \<50 ml/min/1.73m2 * impaired liver function defined as values \>3x the upper limit of normal (uln) for alanine aminotransferase (alt), aspartate aminotransferase (ast), alkaline phosphatase (alp), or total bilirubin * received an investigational agent in another trial within 30 days prior to surgery * known sensitivity to fluorescent light
advanced care coordination and enhanced linkage and retention among transitional re-entrants

Conditions: Hepatitis C

Summary: the overarching goal of this study is to develop a peer-based care coordination intervention for individuals with hepatitis c virus (hcv) who were recently released from correctional settings to promote linkage to and retention in hcv care. the investigators will assess the existing barriers and facilitators of hcv treatment initiation, hcv treatment completion, and sustained virologic response among individuals recently released from a u.s. jail or prisons in a randomized control trial. this study will assess the feasibility and process measures of a peer-enhanced hcv care coordination intervention among recently incarcerated individuals.

the proposed 2-year study will be a block stratified, randomized controlled trial. once consented and enrolled, participants will be randomly assigned to either the peer-enhanced intervention or referred to standard clinical care. the investigators will enroll 80 former inmates with chronic hcv who have been released from incarceration within the past 6 months. it is expected that enrollment will be completed by the fourth quarter of the first year. this will allow sufficient time for hcv treatment uptake, completion, determination of sustained virologic response (svr), and assessment of reinfection. individual participant follow-up will be 3 months on average for treatment, 3 months for svr, and 3 months to assess for reinfection. elucidating the barriers and facilitators in the re-entry care cascade (as well as how they may be overcome) will be critical in designing sustainable models of care for hcv-infected former inmates. the investigators hypothesize that a peer-enhanced strategy will be more effective than standard referral in improving linkage to, and retention in, hcv care among individuals recently released from correctional settings.

Eligibility criteria:
inclusion criteria: * currently incarcerated or recently released from a u.s. jail or prison (6 months) * chronic hcv with documented detectable viral load * 18 years old * fluent in english or spanish * resident of the upstate area of south carolina exclusion criteria: * unable to sign informed consent * life expectancy of less than 1 year * plans to relocate from the upstate area of south carolina in the next 6 months

Keywords: recently incarcerated hepatitis c peer mentor
cardiac resynchronisation study

Conditions: Heart Failure

Summary: this study aims to investigate the effect of a pacemaker device used in heart failure patients which is called cardiac resynchronisation therapy (crt). specifically the investigators aim to investigate if the crt pacemaker has an effect on breathing stability in these patients and particularly breathing stability at night. our theory is that the crt pacemaker may improve the stability of breathing in patients with heart failure.

aim to investigate the effect of cardiac resynchronisation therapy (crt) on chemosensitivity in patients with chronic heart failure with and without sleep disordered breathing (sdb). objective to conduct a physiological observational study to measure hypercapnic ventilatory responses in a group of chf patients before and 3 months after implantation of clinically indicated crt devices. additionally to conduct nocturnal polysomnography to establish if any change in chemosensitivity is related to the presence of sdb at baseline and, where present, any change in sdb after implantation. hypothesis primary hypothesis: crt implantation will be associated with a reduction in the hypercapnic ventilatory response from baseline to 3 months post implantation. additional hypothesis: this reduction in hypercapnic ventilatory response after crt implantation will be greatest in those chf patients with sdb at baseline.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old 2. fulfil the current guidance for the implantation of a crt device; optimal medical treatment for heart failure, broad qrs complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, lvef \<35%, functional impairment as defined by an nyha class of iii-iv 3. clinically stable with no unplanned admission to hospital for preceding 4 weeks 4. no changes in medications for heart failure in preceding 4 weeks 5. able to read and understand patient information sheet and give informed consent exclusion criteria: 1. on positive pressure treatment for known sleep disordered breathing at the time of inclusion 2. other known condition (untreated) likely to significantly disturb sleep eg. restless legs syndrome, pain from any cause etc. 3. pregnancy

Keywords: heart failure
revaluation of wells' clinical prediction score of deep vein thrombosis (dvt) in inpatients with thromboprophylaxis treatment

Conditions: Deep Vein Thrombosis; Thromboses, Venous

Summary: this study aimed (1) revaluating the efficacy of the wells' clinical prediction score for an inpatient population; and the weight of the presence of thromboprophylaxis treatment on the score, and (2) evaluating the correlation of a risk stratification established between a physician specialised in thrombosis and any other doctor.


Eligibility criteria:
inclusion criteria: * any patient addressed to an vascular medicine unit for a clinical suspicion of dvt, with risk stratification through the modified wells score by the referent doctor. exclusion criteria: * patient addressed to our vascular medicine unit for any other reason. * patient addressed to our vascular medicine unit for dvt detection to help in a pulmonary embolism suspicion. * age under 18 yo * patients unable to express their informed consent.

Keywords: wells clinical score thromboprophylaxis
effect of different methodologies on variability of brachial artery flow mediated dilation

Conditions: Endothelial Dysfunction

Summary: flow mediated dilation (fmd) of the brachial artery has been widely used as a non-invasive measure of endothelial function. fmd independently predicts future cardiovascular events and can be readily influenced by pharmacological, dietary or lifestyle interventions. however, the interpretation of fmd data is currently importantly hampered by differences in measurement methodologies and analysis techniques between laboratories. these differences result in large variation of 'normal' values between laboratories, highlighting the need for adopting widely supported and evidence-based guidelines.

background: flow mediated dilation (fmd) of the brachial artery has been widely used as a non-invasive measure of endothelial function. fmd independently predicts future cardiovascular events and can be readily influenced by pharmacological, dietary or lifestyle interventions. need for a review: differences in methodology, guidelines (to control for moderating factors) and analysis techniques contribute to large variation in fmd between laboratories, limiting the widespread use and interpretation of fmd data. objectives: to identify methodological and technological factors that contributes to the variability (i.e. repeatability) of the brachial artery fmd. this will allow for development of quality guidelines for fmd measurement based on systematic data analysis. design: the planning and conduct of the proposed meta-analyses will follow the cochrane handbook for systematic reviews of interventions. the reporting will follow the preferred reporting items for systematic reviews and meta-analyses (prisma) guidelines. data sources: medline, embase chemical abstracts, biosis and the cochrane central register of controlled trials will be searched using appropriate search terms. study selection: observational cohorts and control groups of intervention studies with ≥ 50 subjects. methods: a list of quality criteria for scoring of fmd data will be defined both by expert consensus and by thorough review of the literature. subsequently, a database of brachial artery fmd data (from published data and available individual data) will be compiled. the investigators will investigate which of the quality criteria significantly contribute to the variability of fmd by multiple meta-regression analyses. this data set will also allow us to investigate which quality criteria have the strongest impact on the variability of the fmd, to further refine the list of quality criteria.

Eligibility criteria:
inclusion criteria: * observational cohorts and control groups of intervention studies with ≥ 50 subjects exclusion criteria: * ≤ 50 subjects * any co-intervention in control groups of intervention studies

Keywords: endothelial dysfunction flow mediated dilation brachial artery flow mediated dilation fmd
e-health education program at workplace

Conditions: Health Behavior

Summary: the objective this study is evaluate if an e-health education program at the workplace to contributes to improve quality of life from office workers. and:life style modification; improve physical activity reduces on anthropometric measures; reduces pain and discomfort in the musculoskeletal system

objective: the purpose of this study is evaluate the effectiveness of an e-health education program at the workplace in the quality of life promotion. design: double blinded. randomized clinical trial by cluster. setting: office workers of the universidade publica do estado da bahia, bahia state, brazil. participants: 348 office workers are enrollment, both sex, with over 18 year old. intervention: participants will randomized in: (1) reference group will receive an e-learning health education compose by nine video-class according to the dimensions: 1) musculoskeletal health, 2) eating health e 3) mental health. a video will available by moodle platform every 20 days during six months. in this period the workers will monitored regarding to access the videos and and reinforcements to remain in the program. (2) intervention group: they will receive e-health education program with additional support healthcare tutor everyday.

Eligibility criteria:
inclusion criteria: * technical-administrative workers, computer users for a minimum period of six months. , * signed informed consent form exclusion criteria: * suspected or confirmed pregnant workers at randomization time * mothers what breastfeeding * workers in annual leave.

Keywords: office workers quality of life e-learning occupational health
combination study of cp-751,871 with paclitaxel and carboplatin in advanced lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: phase 1b dose excalation/expansion: identify and characterize safety and tolerability of recommended phase 2 dose of cp-751,871 when administered with paclitaxel and carboplatin phase 1b erlotinib extension: to characterize the safety and tolerability of cp751,871 when administered with paclitaxel, carboplatin and erlotinib. phase 2: to test the efficacy of cp-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer


Eligibility criteria:
inclusion criteria: * diagnosis of advanced/metastatic lung cancer exclusion criteria: * previous treatment with chemotherapy * uncontrolled diabetes * history/active cardiovascular disease

Keywords: non-small cell lung cancer chemotherapy figitumumab insulin-like growth 1 factor receptor igf-ir monoclonal antibody
dementia in migrants living in italy: promoting a diversity-sensitive clinical approach and provision of care

Conditions: Dementia; Alzheimer Disease

Summary: the number of older migrants with cognitive impairment and dementia living in italy and attending national healthcare services is rapidly increasing. there is a need to develop diversity-sensitive policies and practices to include migrants and people with different cultural values in the public health response to dementia.

based on the gaps and barriers identified by the immidem study (gr-2016-02364975), the present project aims to: i) describe the clinical and sociodemographic characteristics of migrants with cognitive disorders living in italy, their health outcomes, and their access to healthcare resources; ii) develop and disseminate screening and assessment tools allowing the cross-cultural cognitive examination of individuals with a migration background; iii) raise awareness about dementia among culturally diverse people and train healthcare professionals in how to provide culturally competent care and support for migrants with cognitive disorders.

Eligibility criteria:
inclusion criteria: * migrant (person who was not born in italy) attending an italian ccdd; * presence of a cognitive impairment. exclusion criteria: * a person without any cognitive impairment.

Keywords: dementia migrants cross-cultural
a phase ii clinical study of stereotactic radiation therapy in patients with high-risk prostate cancer

Conditions: Prostate Cancer; Stereotactic Body Radiotherapy; High-risk; Efficacy; Safety

Summary: stereotactic body radiotherapy (sbrt) has emerged as an effective and safe treatment for low and intermediate-risk prostate cancer(pca). however, there is no study that has investigated the effectiveness and safety of sbrt with pelvic radiation and gross target volume(gtv) boost for high-risk prostate cancer patients yet. the investigators designed a phase ii clinical study of sbrt with pelvic radiation and gtv boost based on mpmri in patients with high-risk prostate cancer.


Eligibility criteria:
inclusion criteria: * 18 years or older * pathologically confirmed high-risk (t3a or gleason score ≥ 8 or a psa \> 20 ng/ml) prostate cancer * a who performance status 0-1 * history of neoadjuvant androgen deprivation therapy(adt) within 6 months before enrollment * patients with pelvic positive lymph node were also included in our study exclusion criteria: * distant metastasis * history of neoadjuvant adt over 6 months before enrollment * history of definitive treatment for prostate cancer such as radical prostatectomy * history of pelvic irradiation; prostate volume≥100 cm3
ames treatment of the impaired leg in chronic stroke patients

Conditions: Stroke; Cerebrovascular Accident; Hemiparesis

Summary: the purpose of this protocol is to determine if individuals who had a stroke more than one year before entering the study and whose ankles remain substantially impaired are able to sense and move the affected leg better after 9-13 weeks of treatment with a robotic therapy device (ames).

our research objective is to develop procedures to rehabilitate those stroke patients who, through conventional therapies, are not brought to a level of maximal recovery. the aims of the proposed project are to obtain a set of data from a total of 20 chronic stroke subjects, all with severe lower extremity disability, between the ages of 18-85, using a robotic therapeutic device placed in a rehabilitation clinic. this data will allow us to quantify the extent to which a combination of robotic-assisted exercise and tendon vibration from the ames beta device induces secondary recovery from the effects of stroke on the lower extremity.

Eligibility criteria:
inclusion criteria: * spastic hemiparesis * at least 12 months post-stroke * can comfortably fit foot in treatment device * functioning proprioception * fugl-meyer le score \>6 and \<23 * minimal hemi-neglect * observable volitional movement of the ankle in either plantar- or dorsi-flexion * cognitively and behaviorally capable of complying with the regimen exclusion criteria: * fractures of treated limb resulting in loss of range of motion * spinal cord injury * deep venous thrombosis * peripheral nerve injury or neuropathy in the affected limb with motor disability * osteoarthritis limiting range of motion * uncontrolled high blood pressure/angina * exercise intolerant * skin condition not tolerant of device * progressive neurodegenerative disorder * uncontrolled seizure disorder * botox treatment within last 5 months * baclofen pump

Keywords: leg robotic device ames stroke cerebrovascular accident rehabilitation
the comparative assessment of mycological efficacy, safety, recurrence, and cost-effectiveness of selenium sulfide 1.8% shampoo versus ketoconazole 2% shampoo in pityriasis versicolor: a double-blind randomized controlled trial

Conditions: Pityriasis Versicolor

Summary: there are several topical treatment for pityriasis versicolor including ketoconazole and selenium sulfide. ketoconazole is a broad spectrum anti-fungal drug from imidazole group that has been reported to be effective in pv. the study aimed to reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (ses2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor. a double blind randomized controlled trial was performed in patients with pv during september-december 2018. patients who involved in this study were allocated to ses2 or ketoconazole 2% based on block randomization. physical examinations, scale provocation test, wood lamp and potassium hydroxide (koh) examination were conducted to evaluate the treatment response and side effects on 7th - 14th day. intention to treat analysis was performed in this study. cost-effectiveness was analyzed by incremental cost-effectiveness ratio (icer).


Eligibility criteria:
inclusion criteria: * having pv characteristic skin lesions,proven by 20% koh scraping test and parker blue-black® ink, with the founding of short hyphae and group spores or short hyphae only * willing to participate in the study by signing the written informed consent * subjects under the age of 18 with permission from parents or guardians. exclusion criteria: * a history of hypersensitivity to the ingredients of the shampoo tested. * having skin abnormalities with impaired skin integrity * in the treatment of topical anti-fungal therapy for less than two weeks or systemic anti-fungal for less than one month. * pregnancy and breastfeeding. * patients with pv lesions on the face.

Keywords: mycological efficacy ketoconazole selenium disulfide 1,8% pityriasis versicolor